POIT BIOP ETFs positioned on POIT BIOP
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.09% | 2 M€ | -.--% | ||
| 0.03% | 7 M€ | -.--% | - | |
| 0.00% | 9 M€ | +5.94% | - | |
| 0.00% | 147 M€ | +5.02% | - | |
| 0.00% | 18 M€ | +3.48% | - | |
| 0.00% | 34 M€ | +2.14% | - |
POINT Biopharma Global Inc. is a radiopharmaceutical company. The Company is engaged in building a platform for the clinical development and commercialization of radioligands that fight cancer. The Company is focused on transforming precision medicine by combining a portfolio of radiopharmaceutical assets, a seasoned management team, a pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like actinium-225 (Ac) and lutetium-177 (Lu). Its pipeline consists of late-stage programs in prostate cancer (PNT2002) and neuroendocrine tumors (PNT2003). Its Lu-PNT2002 is a late-stage prostate-specific membrane antigen (PSMA) targeted radioligand therapy. Its Lu-PNT2003 is a late-stage somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors. Its PNT2004 is a fibroblast activation protein-a (FAP) targeting program being developed for use in multiple tumor types.
Sector
-
